Tvardi Raises $74M to Advance STAT3 Inhibitors for Cancer, Fibrosis

Tvardi Therapeutics Inc., a company targeting a protein essential to cancer cells’ survival and immune evasion, closed a $74 million series B financing. The round will help it advance candidates through multiple midstage trial readouts in cancer and fibrosis, the Houston-based company said. Its lead candidate, TTI-101, is in phase I tests in patients with advanced solid tumors who’ve failed all lines of therapy.

Tvardi is the brainchild of co-founders David Tweardy, head of the division of internal medicine at the University of Texas MD Anderson Cancer Center, and Ron DePinho, MD Anderson’s past president. Tweardy has been studying the signal transducer and activator of transcription 3 (STAT3) gene for 30 years. DePinho, who conceived and launched MD Anderson’s Cancer Moon Shots Program, successfully founded and raised capital for companies including Aveo Pharmaceuticals Inc. and Karyopharm Therapeutics Inc. Together, they raised $25 million in grants to move molecules targeting STAT3 toward the clinic, followed by $9 million in series A financing at the company’s launch in September 2018 to fund early clinical work.

CEO Imran Alibhai, a long-time biotech investor and University of Texas- and Duke University-educated scientist, was hired to lead the company at the end of 2018. He was previously a senior vice president and managing director of Houston-based Dnatrix Inc.
STAT3 is important not only in the tumor itself, but also in the environment around the tumor, Alibhai said. Its activation is observed in about 70% of all cancers and up to95% of hepatocellular carcinomas (the most common type of primary liver cancer), according to research the company presented during a poster session at the 2021American Society of Clinical Oncology meeting.
As an orally bioavailable small molecule, TTI-101 “binds STAT3 and prevents phosphorylation, homodimerization, nuclear translocation, and ultimately, STAT3-mediatedtranscriptional activity,” researchers explained.

To date, the drug has been “incredibly well tolerated,” Alibhai told BioWorld, distinguishing it from other STAT3 inhibitor programs, such as Otsuka Pharmaceutical Co.Ltd.’s tablet-formulated OPB-31121, which the company quit developing following phase I results that reflected grade 3 adverse events (AEs) including lactic acidosis, diarrhea and vomiting. Another STAT3 gene inhibitor co-developed by Ionis Pharmaceuticals Inc. and Astrazeneca plc, danvatirsen, has also run into drug-related AEs in some patients, though the current status of the I.V.-administered candidate was unclear.

Selective targeting is the “secret sauce” of TTI-101, Alibhai said. “If you perturb STAT3 in general, you could potentially cause issues in all cells. So you have to be very specific about how you’re targeting it and only potentially disrupt the nuclear function,” he said.

In Tvardi’s ongoing phase I study so far, TTI-101 has not only side-stepped dose-limiting toxicities, but also shown early signs of clinical benefit, Alibhai said. Multiple participants in the study also saw durable partial responses. The trial enrolled patients with both unresectable hepatocellular carcinoma and locally advanced, inoperable, metastatic and/or treatment-refractory solid tumors without other therapeutic options.

With dose escalation wrapped up in multiple arms of the study, it’s now moving on to dose-expansion cohorts which pave the way for phase II testing in liver cancer next. While the specific design of the phase II trial hasn’t been disclosed yet, Alibhai said investigators will enroll several cohorts of liver cancer patients which could generate signals that could transition very quickly into confirmatory trials.

An expedited trial of TTI-101 in fibrosis could follow. So far, Tvardi has preclinical data demonstrating efficacy in liver fibrosis, idiopathic pulmonary fibrosis and sclerosis, Alibhai said. By the end of next year, the company could also move a second-generation STAT3 inhibitor it is developing, TTI-102, to the clinic. The ‘101 and ‘102 programs share a similar scaffold, but the latter has shown early-on potency three to eight times greater than what has been seen with ‘101.

New investors Slate Path Capital, Palkon Capital, Arrowmark Partners and 683 Capital, led Tvardi’s series B round, with continued funding from existing investors, including Sporos Bioventures. In conjunction with the financing, Jamie McNab, partner at Slate Path Capital, will join Tvardi’s board. The company was Sporos’ first investment. Along the way, it has attracted a number of high-profile scientific advisors, including MD Anderson Department of Immunology Chairman Jim Allison and Keith Flaherty, a professor of medicine at Harvard Medical School who co-founded Loxo Oncology and Scorpion Therapeutics Inc.

“As a physician, I am eager to see the potential of Tvardi’s molecules in diseases of high unmet medical need where STAT3 is a key driver,” Flaherty said.

Read article

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.